|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.580 USD | -1.25% |
|
-10.73% | -36.55% |
| 05-20 | Acurx Pharmaceuticals Highlights FDA's Guidance That Could Accelerate Approval Path for Ibezapolstat | CI |
| 05-12 | Acurx Pharmaceuticals, Inc., Q1 2026 Earnings Call, May 12, 2026 |
Chart: Technical Analysis
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Bearish | Neutral | Neutral |
| Resistance | 1.9 | 6.63 | 9.64 |
| Spread/Res. | -16.84% | -76.17% | -83.61% |
| Spread/Supp. | +5.33% | +17.04% | +17.04% |
| Support | 1.5 | 1.35 | 1.35 |
MarketScreener's Technical Analysis Ratings
| Short Term Timing | |
|---|---|
| Middle Term Timing | |
| Long Term Timing | |
| RSI | |
| Bollinger Spread | |
| Unusual Volumes |
- Stock Market
- Stocks
- ACXP Stock
- Charts Acurx Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
